

## Supporting Information for

## Senolytic and senomorphic agent procyanidin C1 alleviates structural and functional decline in aged retina

Yidan Liu<sup>a,1</sup>, Xiuxing Liu<sup>a,1</sup>, Xuhao Chen<sup>a,1</sup>, Zhenlan Yang<sup>a,1</sup>, Jianqi Chen<sup>a</sup>, Weining Zhu<sup>b</sup>, Yangyang Li<sup>a</sup>, Yuwen Wen<sup>a</sup>, Caibin Deng<sup>a</sup>, Chenyang Gu<sup>a</sup>, Jianjie Lv<sup>a</sup>, Rong Ju<sup>a</sup>, Yehong Zhuo<sup>a,\*</sup>, Wenru Su<sup>a,\*</sup>

<sup>a</sup>State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou, P. R. China

<sup>b</sup>Department of Clinical Medicine, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, P. R. China

<sup>1</sup>These authors contributed equally to this work.

\*Co-corresponding authors: Wenru Su and Yehong Zhuo

State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou 510060, P. R. China. Phone number: +86-20-87330402 (office), +86-13570364296 (mobile)

Email: [suwr3@mail.sysu.edu.cn](mailto:suwr3@mail.sysu.edu.cn), [zhuoyh@mail.sysu.edu.cn](mailto:zhuoyh@mail.sysu.edu.cn)

**Author Contributions:** Yidan Liu, Wenru Su, and Yehong Zhuo conceived the study. Yidan Liu, Xiuxing Liu, and Wenru Su contributed to the design of the experiments. Xuhao Chen, Zhenlan Yang, Jianqi Chen, Weining Zhu, Yangyang Li, Yuwen Wen, Caibin Deng, Chenyang Gu and Jianjie Lv provided study material and/or the assembly of data. Yidan Liu and Xiuxing Liu performed experiments and data collection. Yidan Liu, Xiuxing Liu, Xuhao Chen, and Zhenlan Yang contributed to data analysis and figure preparation. Yidan Liu, Xiuxing Liu, and Xuhao Chen drafted the manuscript. Rong Ju provided experimental guidance in the revision. Wenru Su and Yehong Zhuo supervised the research. Yehong Zhuo provided the financial funding. All authors reviewed and approved the manuscript.

**Competing Interest Statement:** No conflict of interest to declare.

**Classification:** Major – Biological sciences, Minor – Medical Sciences

**Keywords:** cellular senescence, senescence-associated secretory phenotype, senolytics, aging, retina

**This PDF file includes:**

Materials and methods  
SI References  
Figures S1 to S7

50

51 **Materials and methods**52 **Animals and drug treatment**

53 The wild-type C57BL/6J male mice were purchased from Guangdong Medical Laboratory Animal  
54 Center. All animals were raised in a pathogen-free facility in the Animal Laboratories of  
55 Zhongshan Ophthalmic Center. The Institutional Animal Care and Use Committee of Zhongshan  
56 Ophthalmic Center, Sun Yat-sen University, approved the experiments. All mice were housed in a  
57 12-hour light/dark cycle. The mice were divided into the following three groups: (1) Young group  
58 with 6- to 8-week-old mice received standard water and food ad libitum. (2) Aged group with 14-  
59 to 16-month-old mice received standard water and food ad libitum. (3) PCC1 group with 14- to  
60 16-month-old mice received water and tailor-made food ad libitum. PCC1 (#E0478, Selleck,  
61 Houston, TX, USA) was mixed with the regular chow with a concentration of 8 mg/kg, which was  
62 an approximate average dosage of 3.2mg/kg·d for each mouse. The administration of PCC1  
63 lasted for four months before euthanasia.

64

65 **Ultra-performance liquid chromatography (UPLC)**

66 Following PCC1 treatment, the concentration of PCC1 in mouse retina was determined using  
67 UPLC. To enable HPLC analysis, the collected samples, along with a PCC1 standard (#E0478,  
68 Selleck, Houston, TX, USA), were prepared according to a standardized protocol for detection  
69 using ACQUITY UPLC® (Waters, Milford, MA, USA).

70

71 **Immunofluorescence staining**

72 Mice were anesthetized with 1% isoflurane and transcardially perfused with 0.9% saline solution  
73 and 4% paraformaldehyde (PFA). The whole eyeballs were harvested and postfixed in 4% PFA at  
74 4°C for 2 hours. Tissue dehydration was performed overnight using 30% sucrose. Subsequently,  
75 the tissues were embedded in optimal cutting temperature compound (SAKURA, Japan) and  
76 cryosectioned into 14-µm-thick slices. The sections were permeabilized by 0.3% Triton X-100 and  
77 blocked by 2% bovine serum albumin with 10% normal donkey serum. The samples were then  
78 incubated with primary antibodies at 4 °C overnight and a species-compatible secondary antibody  
79 for 2 hours at room temperature. The primary antibodies used were as follows: anti-GFAP  
80 (#ab194324, Abcam) at 1:500, anti-IBA1 (#019-19741, Wako) at 1:500, anti-p16 (#ab211542,  
81 Abcam) at 1:500, anti-PKC alpha (#ab32376, Abcam) at 1:100, and anti-Calbindin (#13176T, Cell  
82 Signaling Technology) at 1:100. For TdT-mediated dUTP nick end labeling (TUNEL), cells were  
83 stained using the TUNEL assay kit (#11684817910, Roche, Basel, Switzerland) according to the  
84 manufacturer's instructions. DAPI solution (Bioss, China) was used for cell nuclei staining.  
85 Images were captured by Nikon confocal microscope (C2+, Nikon, Japan) and processed by  
86 ImageJ software (<https://imagej.nih.gov/ij/>).

87

88 **RNAscope**

89 RNA in situ hybridization was performed using the RNAscope® multiplex fluorescent reagent kit  
90 (ACD Diagnostics, Hayward, CA, USA). Probes used were designed by the manufacturer. Briefly,  
91 fresh frozen sections of mouse eyes were first dehydrated with ethanol in a sequential gradient of  
92 50%,70%, and two rounds of 100% for 5 min each. Subsequently, pretreatment steps involving  
93 hydrogen peroxide and protease IV were performed following the manual instructions. Probes  
94 were then applied and hybridized followed by detection utilizing TSA Vivid Fluorophore 570.  
95 Imaging was accomplished using a Nikon confocal microscope (C2+, Nikon, Japan), with  
96 subsequent processing conducted using ImageJ software (<https://imagej.nih.gov/ij/>).

97

98 **Real-time reverse transcription-quantitative PCR (RT-qPCR)**

99 Total RNA was extracted from mouse retina using the RN002 RNA-Quick Purification Kit  
100 (ESscience, China) according to the manufacturer's instructions. The concentration and purity of  
101 extracted RNA was measured by NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific  
102 Inc., US). cDNA was synthesized with the Evo M-MLV RT Mix Kit (AGbio, China) according to its  
103 standard all-in-one protocol. Quantitative amplification of the target genes was performed with the  
104 SYBR Green Pro Taq HS Premix (AGbio, China) using the Light Cycler 480 Real-Time PCR  
105 System (Roche Molecular Systems, Inc., SUR). The expression level of target mRNAs was  
106 normalized to that of Actb ( $\beta$ -Actin). Primer sequences are listed in the supplementary Table 2-3.  
107

#### 108 Murine electroretinogram (ERG)

109 Full-field ERG recordings were performed using a Celeris D430 rodent ERG system (Diagnosys  
110 LLC, Westford, MA, USA). Briefly, after dark adaptation overnight, the mice were intraperitoneally  
111 anesthetized with pentobarbital sodium solution (100 mg/kg). The pupils were dilated with  
112 compound tropicamide eye drops for 5 min. Each mouse was placed on a platform heater at  
113 37°C. Corneal electrodes with an integrated stimulator were simultaneously placed in both eyes  
114 after lubrication with 1–2% hydroxypropyl methylcellulose. We selected the TOUCH/TOUCH  
115 protocol for bilateral detection and used the unstimulated side as the reference. By default, the  
116 ground electrode is assumed to be unconnected in the TOUCH/TOUCH protocol. We first  
117 performed a scotopic ERG with increasing light intensities from 0.01, 0.1, 1 to 3 cd·s/m<sup>2</sup>. A 10-  
118 min light adaptation was then performed with a background light intensity of 30 cd·s/m<sup>2</sup>. Photopic  
119 ERG were subsequently recorded at 3 and 10 cd·s/m<sup>2</sup>. Ten sweeps were conducted for each  
120 stimulus. The pre-trigger and post-trigger times were set to 50 and 300 ms, respectively, and the  
121 sampling frequency was set to 2000 Hz. The a-wave amplitude was measured by calculating the  
122 difference between the baseline and trough, whereas the b-wave amplitude referred to the  
123 difference between the trough of the a-wave and the peak of the tallest curve.  
124

#### 125 Flow cytometry analysis

126 For analysis of retina, the mice retina from different groups were extracted and the cell  
127 suspensions were isolated by grinding the organs through nylon mesh. For analysis of cell lines,  
128 cells were obtained from different groups through enzyme digestion. Dead cells were excluded  
129 using live/dead dye (#423105, BioLegend, San Diego, CA, USA). Then cells were stained with  
130 the following surface antibodies: CD11B BV605 (#101237, BioLegend), CD73 PE (#127205,  
131 BioLegend) and CD90.2 BV605 (#105343, BioLegend). For intracellular markers staining, cells  
132 were stimulated with 5 ng/mL of phorbol myristate acetate, 500 ng/mL ionomycin, and 1 mg/mL  
133 brefeldin A (Sigma) at 37 °C for 5 h, following by fixation and permeabilization. Then, cells were  
134 stained with the following antibodies: IL-6 PE (#504504, BioLegend), TNF- $\alpha$  BV421 (#506327,  
135 BioLegend), IL-1 $\beta$  PE-Cy7 (#25-7114-80, Invitrogen, Carlsbad, CA, USA) and p21 Alexa Fluor  
136 647 (#ab237265, Abcam, Cambridge, MA, USA) for mouse retina as well as BV2 cells, IL-6 PE-  
137 Cy7 (#501119, BioLegend), p53 PE (#645806, BioLegend), p21 Alexa Fluor 488 (#ab282187,  
138 Abcam, Cambridge, MA, USA) for HRMEC. For the p16 staining, cells were stained with surface  
139 antibodies, fixed, permeabilized, stained with p16 antibody (#ab211542, Abcam), then stained  
140 with Alexa Fluor 647-labeled antibody (#4414S, Cell Signaling Technology, Danvers, USA). To  
141 assess the specificity of the p16 antibody in flow cytometry, additional controls including isotype  
142 control (#ab172730, Abcam) and unstained controls were performed. The isotype control  
143 matches the host species and Ig subclass of the anti-p16 antibody. For the  $\beta$ -galactosidase ( $\beta$ -  
144 GAL) staining, cells were stained with the senescence assay kit (#ab228562, Abcam) according  
145 to the manufacturer's instructions. Finally, the cells were harvested and analyzed by flow  
146 cytometry. For Annexin V and Propidium iodide (PI) staining, cells were stained with the  
147 apoptosis assay kit (#556547, BD Biosciences, San Jose, CA, USA) according to the  
148 manufacturer's instructions. Finally, the cells were harvested and analyzed by flow cytometry.  
149 The flow cytometer (BD LSRFortessa, USA) was used for analysis and the results were analyzed  
150 with FlowJo software (version 10.0.7, Tree Star, Ashland, OR, USA).  
151

#### 152 Cell culture and treatment protocols

153 The BV2 murine microglial cell line was obtained from Zhong Qiao Xin Zhou Biotechnology  
154 Company (Shanghai, China). The human retinal microvascular endothelial cells (HRMEC),  
155 human retinal pigment epithelial cell line ARPE-19 and 661W photoreceptor cell line were  
156 acquired from American Type Culture Collection (ATCC, United States). All cell lines were  
157 cultured at 37°C with 5% CO<sub>2</sub> under normoxic conditions. 661W and APRE-19 cells were cultured  
158 in DMEM/F12 (Gibco) while BV2 and HRMEC cells were cultured in DMEM (Gibco). Complete  
159 medium was prepared by supplementing the respective medium with 10% fetal bovine serum and  
160 1% penicillin/streptomycin. To induce senescence, 661W and APRE-19 cells were subjected to  
161 treatment with 200 μM H<sub>2</sub>O<sub>2</sub> (#7722-84-1, Sigma-Aldrich, St. Louis, MO, USA) in complete  
162 medium for four hours daily over four consecutive days. Cells were otherwise maintained in  
163 complete medium throughout the remaining duration. Following the four-day treatment period,  
164 cells were cultured in complete medium for an additional two days before harvesting. For BV2  
165 cells, the stimulation agent was switched from H<sub>2</sub>O<sub>2</sub> to 10 ng/ml lipopolysaccharide (LPS, #297-  
166 473-0, Sigma-Aldrich). The efficacy of repeated LPS stimulation in inducing cellular senescence  
167 in BV2 cells has been confirmed in the literature (1). The treatment regimen for BV2 cells was  
168 identical to that of 661W and APRE-19 cells. To establish the in vitro diabetic retinopathy (DR)  
169 model, HRMEC cells were treated with 30 mM glucose (Beyotime, China) in complete medium for  
170 two days. The PCC1-treated groups were exposed to the agent at a concentration of 50 μM for  
171 24 hours.

172

#### 173 Cell viability assay

174 Senescent or control cells ( $5 \times 10^3$ /well) were seeded into a 96-well plate, treated with various  
175 concentrations of PCC1 (5–200 μM), and incubated at 37°C in a humidified incubator under 5%  
176 CO<sub>2</sub> for 24 hours. Cell viability was determined using a Cell Counting Kit-8 (CCK8, #GK10001,  
177 GLP BIO, Montclair, CA, USA) according to the manufacturer's instructions.

178

#### 179 Enzyme-linked immunosorbent assay (ELISA)

180 The serum from mice were determined using the mouse IL-1 beta ELISA Kit (#88-7013-22,  
181 invitrogen), mouse IL-6 ELISA Kit (#88-7064-88, invitrogen) and mouse TNF alpha ELISA Kit  
182 (#88-7324-88, invitrogen). For HRMEC cells, supernatants of different groups were collected at  
183 the end of incubation. Interleukin-6 (IL6) and Vascular Endothelial Growth Factor-A (VEGF-A)  
184 were measured with human IL-6 ELISA kit (#88-7066-88, invitrogen) and VEGF-A Human ELISA  
185 Kit (#BMS277-2, Invitrogen) respectively, according to manual guide.

186

#### 187 Single-cell RNA sequencing analysis

188 10× Genomics kit was used to construct barcoded libraries. The sequenced data was initially  
189 processed in Cell Ranger (version 7.0.0) count pipeline and integrated by Cell Ranger aggr  
190 command. Subsequent analysis was performed in R using Seurat package (version 4.1.1)(2) with  
191 the default parameters unless otherwise specified. Cells with more than 200, fewer than 4000  
192 genes, and less than 20% mitochondrial genes were retained after quality control. We obtained  
193 72,054 cells after quality control (young, 37,150 cells; aged, 7,980 cells; and PCC1-treated aged  
194 mice, 26,924 cells) for downstream analysis. The R package harmony (version 0.1.0) was used to  
195 correct the batch effect of different sequencing samples. The scRNA-seq data of nAMD and DR  
196 was downloaded from Gene Expression Omnibus (GEO) database under the accession number  
197 GSE135922 and GSE178121. Metadata and expression count were imported into R to perform  
198 subsequent analysis. Differential expression analysis was performed by "FindMarkers" function  
199 integrated in Seurat. Genes with  $|\text{Log}_2(\text{Fold Change})| > 0.25$  and P value  $< 0.05$  were defined  
200 as differentially expressed genes (DEGs).

201

#### 202 Gene functional analysis

203 Function annotation of DEGs was conducted by Gene Ontology (GO) analysis in the Metascape  
204 (3). Several representative GO terms or pathways were demonstrated in R package ggplot2  
205 (version 3.3.6).

206

207 Cell-cell interaction analysis  
208 Intracellular cell-cell communication was predicted in the R package CellChat (version 1.4.0) (4).  
209 Signaling pathway across the three groups and interaction networks were visualized, and the  
210 expression of ligands and receptors was presented in violin plots.

211  
212 Senescent cells identification  
213 In order to avoid the bias, we first performed the stratified sampling of the three groups (Young,  
214 Aged, PCC1) according to the number of each cell type to ensure the same number of total cells  
215 from three groups. We then conducted gene set variation analysis (GSVA) of integrated  
216 expression matrix using “enrichit” function from R package gsva (version 1.4.0) referring to the  
217 SenMayo gene set (5). Cells of top 10% ES were manually defined as senescent cells.

218  
219 Gene set score analysis  
220 Gene related to NF- $\kappa$ B and p38MAPK signaling pathway were downloaded from MSigDb  
221 (<https://www.gsea-msigdb.org/gsea/index.jsp>). Gene set scores were calculated by the Seurat  
222 function “AddModuleScore” from R package Seurat.

223  
224 Statistical analysis  
225 Data were presented as mean  $\pm$  SD (standard deviation). Two-tailed Student’s t-test and Mann-  
226 Whitney U test were used for two group comparisons depending on the normality and equal  
227 variance of data. One-way ANOVA and Kruskal-Wallis test with Bonferroni post-hoc test were  
228 used for statistical analysis of variables in multiple groups depending on the normality and equal  
229 variance of data. P value < 0.05 was considered statistically significant. The sample sizes and P  
230 values were both indicated in the figure legends. The statistical analysis was performed by  
231 GraphPad Prism 9 (GraphPad Software, United States) and R software (version 4.1.3).


232  
233 Data availability statement  
234 The scRNA-seq data are deposited in the Genome Sequence Archive in BIG Data Center, Beijing  
235 Institute of Genomics (BIG, <https://ngdc.cncb.ac.cn/gsa/>), Chinese Academy of Sciences, under  
236 the GSA Accession No. CRA011488. The data analysis pipeline used in scRNA-seq follows the  
237 description on the 10X Genomics and Seurat official websites. The analysis steps, functions, and  
238 parameters used are described in detail in the Materials and methods section.

239


## 240 **SI References**

- 241 1. H.-M. Yu, *et al.*, Repeated Lipopolysaccharide Stimulation Induces Cellular Senescence  
242 in BV2 Cells. *Neuroimmunomodulation* **19**, 131–136 (2012).
- 243 2. A. Butler, P. Hoffman, P. Smibert, E. Papalexi, R. Satija, Integrating single-cell  
244 transcriptomic data across different conditions, technologies, and species. *Nat. Biotechnol.* **36**,  
245 411–420 (2018).
- 246 3. Y. Zhou, *et al.*, Metascape provides a biologist-oriented resource for the analysis of  
247 systems-level datasets. *Nat. Commun.* **10**, 1523 (2019).
- 248 4. S. Jin, *et al.*, Inference and analysis of cell-cell communication using CellChat. *Nat.*  
249 *Commun.* **12**, 1088 (2021).
- 250 5. D. Saul, *et al.*, A new gene set identifies senescent cells and predicts senescence-  
251 associated pathways across tissues. *Nat. Commun.* **13**, 4827 (2022).
- 252

253 **Supplementary Figure and Legend**



254 **Fig. S1** The aged retina showed decreased photopic responses  
255 A. Bar charts showing the quantification of photopic ERG amplitudes (n = 6/group). Data are  
256 shown as mean ± SD and P values were analyzed using unpaired two-tailed Student's *t*-test; ns,  
257 non-significant; \*\*\*P < 0.001.  
258 B. To assess the specificity of the p16 antibody in flow cytometry, additional controls including  
259 isotype control and unstained controls were performed. Flow cytometry histogram showing the  
260 fluorescence of p16 in senescent BV2 cells stained with different combinations of antibodies  
261 (Abbreviations: Ab1, primary antibody; Ab2, secondary antibody).  
262



263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277

**Fig. S2** Long-term PCC1 treatment relieved functional and structural impairment in aged retina by both senolytic and senomorphic effects

A-F. Representative flow charts (left) and quantification (right) of the proportion of p16 and p21 in 661W (A-B), BV2 cells (C-D), p53 and p21 in ARPE-19 cells (E-F).


G-I. Bar plots showing the relative mRNA expression levels of senescence markers and several SASP-related genes were detected by real-time quantitative PCR between control, senescent and PCC1-treated senescent groups in 661W (G), BV2 (H) and ARPE-19 (I) cells (n = 3/group).

J. UPLC analysis revealed a detectable PCC1 peak (at 2.716 min) in the retina.

K. Bar plot showing relative mRNA expression levels of several SASP-related genes were detected by RT-qPCR between control and PCC1-treated aged mice (n = 3/group).

L. Bar charts showing the quantification of photopic ERG amplitudes (n = 6/group).


Data are shown as mean ± SD. P values were analyzed using one-way ANOVA with Bonferroni post-hoc test (A-I) or unpaired two-tailed Student's *t*-test (K-L); ns, non-significant; \*P < 0.05; \*\*P < 0.01; \*\*\*P < 0.001, \*\*\*\*P < 0.0001.



278 **Fig. S3** The seotherapeutic effects of PCC1 treatment on aged retina evaluated by single-cell  
 279 analysis  
 280 A. Dot plot showing markers genes (rows) that uniquely mark different cell types in mouse retina  
 281 (columns). The size of the dot indicates the percentage of cells expressing the gene, and the  
 282 color represents the average expression level of the gene in the indicated cell types.  
 283 B. Circle plots showing the inferred CADM signaling networks among three groups. Edge width  
 284 represents the communication probability.




285 C. Violin plots showing the expression of the ligand-receptor involved in the inferred CADM  
286 signaling pathway.  
287 D. Volcano plot showing Rescue-DEGs of RPE.  
288 E. Bar plots showing the relative mRNA expression levels of several Rescue-DEGs detected by  
289 real-time quantitative PCR between control, senescent and PCC1-treated senescent groups  
290 ARPE-19 cells (n = 3/group).  
291 F. Bar plot showing the ratios of different retinal cell types of aged mice compared to young mice  
292 derived from scRNA-seq data.  
293 G. Representative flow charts (left) and quantification (right) of the proportion of microglia from  
294 retina of young and aged group (n = 5/group).  
295 Data are shown as mean  $\pm$  SD. P values were analyzed using one-way ANOVA with Bonferroni  
296 post-hoc test (E) or unpaired two-tailed Student's t test (G); \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001,  
297 \*\*\*\*P < 0.0001.



298  
299  
300  
301  
302  
303  
304  
305


**Fig. S4** Senescent cells and SASP factors were reduced after PCC1 treatment  
 A. Heatmap showing the expression pattern of SASP-related genes in three groups.  
 B. Representative confocal images of RNAscope analysis of Cdkn2a, Il1b, Tnfa and Il6 on retinal frozen sections from the young (upper panel), aged (middle panel) and PCC1-treated (lower panel) mice (n = 6/group). The positive control was detected using the Polr2a probe and the negative control was detected using the DapB probe. The arrow indicates positive cells in the retina. Scale bar 100 μm.  
 C. Bar plot showing the proportions of senescent cells in various retinal cell types in the retina.

306 D. Bar plots showing quantification of the MFI of  $\beta$ -gal in CD11B+ microglia cells, CD90.2+ cells  
307 and CD73+ rod photoreceptor cells.  
308 Data are shown as mean  $\pm$  SD. P values were analyzed using Kruskal-Wallis test with Bonferroni  
309 post-hoc test (B) or one-way ANOVA with Bonferroni post-hoc test (D); \*P < 0.05, \*\*\*P < 0.001,  
310 \*\*\*\*P < 0.0001.  
311  
312




313 **Fig. S5** Experimental validation of depletion of senescent cells both in vivo and in vitro by PCC1  
 314 A-B. Bar plot showing CCK-8 assay on control and senescent cells of 661W (A) and BV2 cell line  
 315 (B) upon treatment of PCC1 (n=5/group).  
 316 C-D. Representative flow charts (left) and quantification (right) of AnnexinV/PI apoptotic assay on  
 317 control and senescent cells of 661W (C) and BV2 cell line (D) upon treatment of PCC1  
 318 (n=5/group).  
 319 E. Ridge plots showing the expression of SASP factors in each cell type in retina with lighter color  
 320 indicating the aged group and darker color indicating the PCC1-treated aged group. The dashed  
 321 lines indicate the mean values.  
 322 F. Heatmap showing the expression level of indicated genes in microglia in single-cell data.

323 G. Representative flow charts (left) and quantification (right) of the proportion of IL-6, IL-1B and  
324 TNF- $\alpha$  in BV2 cells among three groups (n=5/group).  
325 Data are shown as mean  $\pm$  SD. P values were analyzed two-tailed unpaired Student's t-test (A-D)  
326 or one-way ANOVA with Bonferroni post-hoc test (G-I); ns, non-significant; \*P < 0.05, \*\*\*P <  
327 0.001, \*\*\*\*P < 0.0001.  
328



329 **Fig. S6** Cellular senescence was increased in neo-vascular age-related macular degeneration  
 330 **A.** Dot plot showing markers genes (rows) that uniquely mark different cell types in RPE and  
 331 choroid (columns). The size of the dot indicates the percentage of cells expressing the gene, and  
 332 the color represents the average expression level of the gene in the indicated cell type.

- 333 **B.** t-SNE plot showing the ES of SASP-related genes of RPE and choroidal cells.  
334 **C.** t-SNE plot showing the distribution of senescent cells in the RPE and choroid between the two  
335 groups.  
336 **D.** Bar plot showing the percentage of senescent cells in all retinal cells of two groups.  
337 **E.** Chord plot showing the interactions between the senescent cells and target cells, including all  
338 cell types in the RPE and choroid.  
339 **F.** Chord plot showing the interactions between the senescent cells and the target cells,  
340 endothelial cell and pericytes.  
341 **G.** Violin plot showing the expression of the ligand-receptors involved in the inferred VEGF  
342 signaling pathway.  
343 **H.** Violin plot showing the expression of the ligand-receptors involved in the inferred ANGPTL  
344 signaling pathway.  
345



346  
347  
348  
349  
350

**Fig. S7** Cellular senescence was increased in diabetic retinopathy  
**A.** Violin plot showing the expression of the ligand-receptors involved in the inferred NOTCH signaling pathway.  
**B.** Violin plot showing the expression of the ligand-receptors involved in the inferred IL-6 signaling pathway.



- 351 **C.** Dot plot showing markers genes (rows) that uniquely mark different retinal cell types  
352 (columns). The size of the dot indicates the percentage of cells expressing the gene, and the  
353 color represents the average expression level of the gene in the indicated cell type.  
354 **D.** Bar plot showing the percentage of senescent cells in all retinal cells of two groups.  
355 **E.** Bar plot showing the proportions of senescent cells in different retinal cell types in the retina.  
356 **F.** Chord plot showing the interactions between the senescent cells and target cells, including all  
357 cell types in the retina.  
358 **G.** Violin plot showing the expression of the ligand-receptor involved in the inferred MIF signaling  
359 pathway.  
360 **H.** Violin plot showing the expression of the ligand-receptors involved in the inferred TGFb  
361 signaling pathway.  
362 **I.** Violin plot showing the expression of the ligand-receptors involved in the inferred PTN signaling  
363 pathway.  
364  
365

366 **Supplementary Table and Legend**

367

368 **Table S1.** PCC1 deletes senescent cells in each cell type of retina assessed in scRNA-seq data

	A	B	C	D	E	F	G
Rod	405	4089	9.9%	373	4341	8.59%	1.31%
Cone	16	226	7.08%	11	171	6.43%	0.65%
RBC	7	51	13.73%	4	50	8%	5.73%
CBC	17	62	27.42%	13	98	13.27%	14.15%
AC	5	24	20.83%	3	15	20%	0.83%
HC	0	4	0%	0	4	0%	0%
RGC	2	6	33.33%	0	7	0%	33.33%
Macroglia	161	247	65.18%	92	212	43.4%	21.78%
Microglia	86	105	81.9%	22	61	36.07%	45.83%
RPE	237	260	91.15%	51	112	45.54%	45.61%
VEC&Pericyte	13	19	68.42%	10	22	45.45%	22.97%

369

A = The number of predicted senescent cells in each cell type of Aged group

370

B = The number of total cells in each cell type of Aged group

371

C = A/B = The ratio of senescent cells in each cell type of Aged group

372

D = The number of predicted senescent cells in each cell type of PCC1 group

373

E = The number of total cells in each cell type of PCC1 group

374

F = D/E = The ratio of senescent cells in each cell type of PCC1 group

375

G = C-F = Reduced ratio of senescent cells in each cell type by PCC1

376

377

378

379  
380

**Table S2.** A list of mouse primer sequences for qRT-PCR assays.

Target name	Forward (5'-3')	Reverse (5'-3')
p16	GCTCAACTACGGTGCAGATTC	GCACGATGTCTTGATGTCCC
p21	CCTGGTGATGTCCGACCTG	CCATGAGCGCATCGCAATC
IL1B	GAAATGCCACCTTTTGACAGTG	TGGATGCTCTCATCAGGACAG
CCL3	TGTACCATGACACTCTGCAAC	CAACGATGAATTGGCGTGGAA
ERN1	ACACTGCCTGAGACCTTGTTG	GGAGCCCGTCCTCTTGCTA
CSF2	GGCCTTGAAGCATGTAGAGG	GGAGAACTCGTTAGAGACGACTT
MMP3	TTGATGGGCCTGGAACAGTC	AGTCCTGAGAGATTTGCGCC
SERPINE1	TGACGTCGTGGAAGTGC	GAAAGACTTGTGAAGTCGGC
ACTB	GGCTGTATTCCCCTCCAT	CCAGTTGGTAACAATGCC

381  
382

383

**Table S3** A list of human primer sequences for qRT-PCR assays.

Target name	Forward (5'-3')	Reverse (5'-3')
p16	GATCCAGGTGGGTAGAAGGTC	CCCCTGCAAACCTTCGTCCT
p21	TGTCCGTCAGAACCCATGC	AAAGTCGAAGTTCCATCGCTC
IL1B	ATGATGGCTTATTACAGTGGCAA	GTCGGAGATTTCGTAGCTGGA
CCL3	AGTTCTCTGCATCACTTGCTG	CGGCTTCGCTTGGTTAGGAA
ERN1	CACAGTGACGCTTCCTGAAAC	GCCATCATTAGGATCTGGGAGA
CSF2	TCCTGAACCTGAGTAGAGACAC	TGCTGCTTGTAGTGGCTGG
MMP3	AGTCTTCCAATCCTACTGTTGCT	TCCCCGTCACCTCCAATCC
SERPINE1	ACCGCAACGTGGTTTTCTCA	TTGAATCCCATAGCTGCTTGAAT
ENO2	AGCCTCTACGGGCATCTATGA	TTCTCAGTCCCATCCAACTCC
PKM	ATGTCGAAGCCCCATAGTGAA	TGGGTGGTGAATCAATGTCCA
MAP1B	ATCTCGACACTCTGCAAGATTCT	CTGGTCCAAGTTGCACTCAAT
HSP90AA1	CATAACGATGATGAGCAGTACGC	GACCCATAGGTTACCTGTGT
ATF2	AATTGAGGAGCCTTCTGTTGTAG	CATCACTGGTAGTAGACTCTGGG
NDUFA10	GTGCAAACCTGCGCTATGGAAT	CAGGAAAGTGCTTGAAGCCTA
APPL1	ACTTGGGTACATGCAAGCTCA	TCCCTGCGAACATTCTGAACG
ACTB	CATGTACGTTGCTATCCAGGC	CTCCTTAATGTCACGCACGAT

384